Opko Health Inc., of Miami, offered data from its completed 12-month hGH-CTP phase II pediatric growth hormone deficiency clinical study in two oral presentations at the 54th Annual Meeting of the European Society for Pediatric Endocrinology in Barcelona, Spain.